Part IThe Story
There are three lines on the slide. The blue line belongs to animals that had a heart attack and then received an injection of water. One year later, about 15 percent of them are still alive. The green line belongs to animals given gene therapy, a treatment that cannot be switched off once it is delivered, and it falls faster than the blue. "You kill the animal faster than if you do nothing," the man at the lectern told a TEDx audience on Beacon Street in Boston, "because it keeps making VEGF, and you have the whole body going crazy because it's not supposed to be that way." The red line is the one he came to talk about. It shows a single injection of messenger RNA encoding a protein called VEGF-A, given within 48 hours of the infarct. "One dose," he said. "Not daily, not quickly, one dose."
The man was Stéphane Bancel, chief executive of a Cambridge company then called ModeRNA Therapeutics, and at the moment he described the red line he had no drug in a human being. He said as much near the end: "we really hope that within a year or two, we are going to be in the clinic." What he had was a mechanism and a slide. He also had a very old question, one so obvious that the obviousness was the strangest thing about it. He explained that the body already runs on messenger RNA, that every cell reads it "trillions of time a day," and so "mRNA are drugs, why not?" Then he ended the talk with the question that would become, depending on the year and the observer, a scientific program, a $7.5 billion IPO, a pandemic countermeasure administered to hundreds of millions of people, an $18 billion windfall, a cautionary tale, and a second act: "What if mRNA could be a drug?"
The transcript of the talk preserves a small accident worth keeping. Describing the history of biotechnology, Bancel said, as the transcriber rendered it, that it was "a very bad symmetry of dead companies." In a Marseille-born executive's English, he almost certainly meant cemetery. The slip is fitting, because the whole enterprise runs on the gap between a message as it is sent and the message as it is received.
The detail from that slide that matters most, the one the rest of this story keeps coming back to, is what happens to the red-line dose after it is injected. "The mRNA gets degraded, after 48 hours it's gone," Bancel said, "but the VEGF is here and it has instructed the stem cell to regrow your heart." The instruction disappears, and the tissue it called for remains.
By the Numbers
The Moderna Arc
$621MRaised in Moderna's December 2018 IPO, then the largest biotech IPO in history
94.1%Efficacy of mRNA-1273 in the Phase III trial behind its U.S. emergency authorization
$18.47BModerna revenue in 2021, up from $60 million in 2019
$1.94BModerna revenue in 2025, alongside a $2.8 billion net loss
7.3%Bancel's ownership stake, the largest of any individual holder
177%One-day share gain on August 19, 2026, after Phase III melanoma results
The engineer's son and the doctor's son
He was born in Marseille in 1972 to an engineer and a physician. That is nearly all the public record holds about his parents, except for one fact that Bancel himself supplied, decades later, in a 2022 interview with the Posse Foundation: they divorced when he was eight. One parent built things and the other healed people, and their son grew up between the two households, liking computers, mathematics, and science. In April 2021, with his company's vaccine in arms across the developed world, the British magazine MoneyWeek gave him the headline that probably comes closest to how he sees himself: "the maths nerd who struck vaccine gold."
The education reads less like a résumé than like a long negotiation between the two professions he was born into. He started with engineering at the École Centrale Paris, one of France's grandes écoles, the kind of institution that produces people who run ministries and nuclear programs. Then he crossed an ocean to the University of Minnesota to study biological engineering, the discipline that treats living cells as systems to be specified, built, and debugged. He took a master's degree at each institution. After that came an MBA from Harvard Business School, which teaches people to turn a mechanism into a market.
His first career was not in science at all. At Eli Lilly he was a sales director, and he rose to run the company's operations in Belgium, a small market where a young executive learns that a drug's value is set as much by reimbursement committees and distribution contracts as by chemistry. In 2007 he went home, in a sense, to become chief executive of bioMérieux, a French diagnostics company. Stat later reported that he was credited with improving its margins. Diagnostics is a business of information: a test tells you what is wrong without fixing anything. Bancel spent four years selling the answers to questions and then left to work on instructions.
In 2011 he took the top job at a year-old startup in Cambridge, Massachusetts. Moderna had been founded in September 2010 by Derrick Rossi, Timothy Springer, Kenneth Chien, Robert Langer, and Noubar Afeyan. The founders list reads like a faculty roster with a venture capitalist attached, and none of the founders took the job Bancel took. The name was a compression of three words: modified, RNA, modern. For eight years it was styled ModeRNA, with the capital letters doing the explaining. In 2018 the company dropped the typographic joke and became Moderna, a word that now needed no gloss.
Today Bancel is a partner at Flagship Pioneering and has sat on the boards of Indigo Agriculture, the life-sciences toolmaker Qiagen, and Boston's Museum of Science. He lives in Boston with his wife, Brenda, and their two children. Their family philanthropy carries both their names. By May 2023, Forbes estimated his fortune at $4.1 billion.
A copy, so as not to damage the original
Bancel's explanation of biology is worth reading slowly. He talks about the subject the way an engineer describes a well-designed system he admires and would like to have built himself.
"When your body needs a protein, what does it do?" he asked the Beacon Street audience. "It basically uses the information of the genes in your DNA. And in order not to damage your DNA, it makes a little copy of only what it needs, only the gene it needs." The copy is messenger RNA. It travels to the ribosome, "a little machine," which reads it and assembles a protein. "And Voilà!, you've just made insulin." In the transcript, the French word gets an exclamation point.
This account packs in a view of medicine. The genome is the archive, precious and not to be handled. Messenger RNA is a working copy, disposable by design, and that disposability is a feature: a temporary instruction can be issued, carried out, and withdrawn without anyone touching the original. Bancel went on to describe the biotechnology industry's first generation, Genentech and Amgen, which made proteins in yeast and bacteria, filled syringes with them, and injected them. The second generation, gene therapy, tried to install the missing DNA permanently in the patient. Bancel was unsparing about the result. Forty years on, he said, there was "only one gene-therapy product approved for patients. One!" There were more than 6,000 rare diseases, "and the number is going up every week."
He chose one of those diseases to make the stakes concrete. Crigler-Najjar is caused by a single error in a gene called UGT1A1 on chromosome 2: "one mistake out of three billion bases." There was no treatment. To survive, patients spent twelve hours a day under phototherapy lamps, and "by the time this little guy is 18 he is going to die because his body is going to be too big, the phototherapy will not work any more." The image of a child lying under a lamp for half of every day, kept alive by light until he outgrows it, is the most affecting moment in the talk. It also amounts to a business thesis. Most of the proteins the body needs stay inside the cell, and those, he said, were "totally undrugable with any technology available today."
Two obstacles had kept anyone from turning that thesis into a company. The first was immunological. Viruses carry RNA, "so if we inject mRNA in a patient, what happens? Your body thinks you've just got the flu." The second was chemical: messenger RNA was thought to survive only minutes in the body, "and I don't think a drug that you have to inject yourself every couple of minutes would be a good drug either." Moderna's founding claim was that both obstacles could be engineered away. Years later, the published chemistry of the company's COVID-19 vaccine would show one way it was done: every uridine in the 4,101-nucleotide sequence is replaced with N1-methylpseudouridine. That is the modified in the company's name, and it is what keeps a working copy from looking like an intruder.
The academic who taught Bancel what the platform could do for the heart was Kenneth Chien, one of Moderna's academic co-founders, a cardiologist who had, in Bancel's words, "spent his life studying hearts" and who held a professorship at the Karolinska Institute in Sweden. Chien's career was a thirty-year search for the right vehicle for a single idea. Every heart carries dormant stem cells "until the day we die," and a protein called VEGF-A can tell them to "go back to work." He first tried delivering the recombinant protein, made in E. coli, but it scattered through the bloodstream and the doses needed to work caused too many side effects, so the drug failed in trials. Ten years later he tried gene therapy, which could not be stopped once started. When he saw messenger RNA, which makes a burst of protein and then decays, he said, as Bancel recounted, "That's exactly what I've been looking for for the last 30 years!"
Chien is a scientist who held the right instruction for three decades and lacked only the means to send it. That makes him an apt first character in Bancel's story.
Eighteen months without a website
There is a particular way of building that comes from believing you hold something that could be ruined by attention. Bancel described his version on Beacon Street in the language of mountaineering. "Let's think about it like we are climbing Mt Everest for the first time," he said the founding team had told itself. "How do you climb it? There is no map! Do you go right? Left?" The question behind the metaphor was blunter: "How do we not screw this unbelievable technology so we bring it to patients that are suffering?"
He then listed the decisions, each of which ran against the habits of the industry.
The first concerned money. "We first chose to have only one investor. Most biotech companies have many investors, to derisk, we said only one because we wanted to focus on building the company, not people fighting for how much money they were going to make." He did not name the investor from the stage. Today the company's chairman is Noubar Afeyan, a founder, and Bancel himself is a partner at Flagship Pioneering.
The second concerned animals. Most young biotechs test on mice and rats, which Bancel called "nice and cute" before dismissing them: "if it worked, it will be known, cancer would have been cured 10 years ago because we can cure cancer in mice." He went to primates instead. "We went straight into monkeys. Very atypical. Cost a bloody fortune."
The third concerned silence.
— Stéphane Bancel, TEDxBeaconStreetWe said: "We need to stay focused on the science, this is too big an idea to be defocused." So for 18 months, no website. No press release, no nothing. Just focus on the science.
The silence was a strategy, and it succeeded well enough that the press found its own words for it. In March 2013, Boston Magazine ran a profile titled "The NEXT Next Big Thing." On September 13, 2016, Stat published a long investigation under the headline "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups." It reported that Bancel ran a highly secretive culture with little outside review of the company's science. In February 2017, Science used a headline that conceded the point while appearing to break it: "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines."
The $2 billion was real. Between 2011 and 2017, Moderna raised about that much in venture capital, at the time an almost unprecedented sum for a private company with no approved product and, for much of that period, almost no peer-reviewed disclosure of how its technology worked. The money bought primate studies, a manufacturing capability, and the time to fail privately. It also bought a reputation that would follow the company into 2020: the suspicion that its silence was hiding something rather than protecting something. Bancel likely regarded those as the same thing seen from different distances.
His own summary of the arithmetic was characteristically frank. Biotechnology "costs a bloody fortune and it's complicated." In the same passage he said, or at least the transcript has him saying, "Less than 1% of the drugs started by biotech companies never make it to the market." The double negative reverses his meaning. He clearly intended to say that almost nothing survives. It is the kind of slip a man makes when he has said the true version so often that the words no longer register.
Selling options on a platform
If the secrecy was one half of Bancel's early method, the other half was its opposite: a steady stream of deals that put the platform's possibilities in front of the largest companies in pharmaceuticals and let them pay to be first in line.
The first major deal came in March 2013, when The Boston Globe reported that Moderna was in line for a $240 million licensing agreement with AstraZeneca, covering cardiovascular, metabolic, and renal diseases as well as cancer. The same year, the Defense Advanced Research Projects Agency awarded the company a $25 million grant under a program whose name was a bureaucratic tongue-twister: Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats, or ADEPT-PROTECT. Its stated goal now reads like a prophecy filed in triplicate: an mRNA vaccine capable of suppressing a global pandemic within sixty days.
In January 2014 came an agreement with Alexion Pharmaceuticals to develop treatments for ten diseases. That same month Moderna created its first venture, Onkaido Therapeutics, with a $20 million capital commitment and a mandate to focus "exclusively on developing mRNA-based oncology treatments." A second venture, Valera, launched in January 2015 for "viral, bacterial and parasitic infectious diseases," and employees of Valera and Moderna developed a Zika vaccine candidate that appeared in Cell in February 2017. A third, Elpidera, was announced in May 2015 to carry forward the Alexion rare-disease work. Merck signed on for cancer in 2015. Vertex followed in 2016 with a deal reported at more than $315 million to pursue cystic fibrosis. In January 2016 the Bill & Melinda Gates Foundation committed at least $20 million in grants. The first mRNA vaccine Moderna developed was for influenza, in 2015.
Laid out in sequence, the pattern looks less like a pipeline than like a portfolio of options written on a single underlying asset. Each venture and partner bought exposure to one application of the same idea, so that if the platform worked anywhere, it would prove itself everywhere. The structure suited a company whose central claim was that the medicine was a format, a delivery system for instructions, and not a particular molecule.
Options can expire worthless, and one did. In July 2017, Alexion ended the partnership after safety issues kept the work from reaching human trials. Stat gave the story a headline that showed how the press regarded Moderna by then: "Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline." The ten diseases became zero. The rare-disease ambition, the one that had opened the Beacon Street talk with a child under a phototherapy lamp, hit exactly the obstacle Bancel had described in that talk.
He did not retreat. In July 2018 Moderna opened a 200,000-square-foot facility in Norwood, Massachusetts, for manufacturing, preclinical, and clinical work. A local business journal reported that the $110 million site had been "built with expansion hopes." Building a factory before you have a product is a statement of belief or of stubbornness, and in Bancel's case the two are hard to separate.
That December, Moderna went public in what was then the largest initial public offering ever by a biotechnology company. It sold 27 million shares at $23 each, raised $621 million, and was valued at about $7.5 billion. Fortune asked what the deal said about the industry's future. The company's revenue for the following year, 2019, came to $60 million, and its net loss to $514 million. The market was valuing a format that had not yet produced a single approved product.
Sixty days
On January 24, 2020, Reuters reported that scientists, "with Wuhan virus genetic code in hand," had begun work on a vaccine. Moderna's candidate had a codename, mRNA-1273, and its design drew on outside work. It encoded a version of the coronavirus spike protein carrying a modification called 2P, two stabilizing mutations in which the original amino acids are replaced with prolines. That modification came from researchers at the University of Texas at Austin and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases. The platform that DARPA had funded in 2013 to answer a pandemic within sixty days was now facing an actual pandemic.
On March 16, 2020, the National Institutes of Health announced that a Phase I clinical trial of the vaccine had begun in partnership with NIAID. In April, the Biomedical Advanced Research and Development Authority, an office of the U.S. Department of Health and Human Services, allocated up to $483 million. Moderna signed a partnership with the Swiss manufacturer Lonza Group to supply 300 million doses a year. In early April, Forbes reported that Bancel's roughly 9 percent stake had crossed $1 billion in value as the stock rose on news of imminent Phase II trials. He had become a billionaire on the strength of an experiment that had not yet finished.
The supply chain assembled that spring stretched across a continent and an ocean. The first step, synthesizing the DNA plasmids used as templates for the messenger RNA, went to a contractor called Aldevron in Fargo, North Dakota. Lonza would make the vaccine itself at a plant in Portsmouth, New Hampshire, and another in Visp, Switzerland, and later at Geleen in the Netherlands. CordenPharma supplied the lipids. Catalent in Bloomington, Indiana, and Laboratorios Farmacéuticos Rovi in Spain would fill and package the vials. Norwood, the factory built "with expansion hopes," would make vaccine too.
The government's money kept coming. From 2020 through 2021, Moderna received $955 million from Operation Warp Speed, with $4.9 billion committed in total to produce 300 million doses. By one accounting, BARDA funded 100 percent of the cost of bringing the vaccine to FDA licensure, and total U.S. government funding reached $2.5 billion. Private donors contributed as well. The Dolly Parton COVID-19 Research Fund gave $1 million, so a country singer from the Smoky Mountains became a footnote to the Cambridge company's breakthrough. The company that had once insisted on a single investor was now financed by the federal government of the United States.
In May 2020, Moderna released preliminary antibody results from its earliest human study. The results covered only eight of the forty-five people enrolled, were not peer-reviewed, and went directly to the financial markets. The company then announced an immediate $1.25 billion share sale at a $30 billion valuation, and Bancel discussed the raise on CNBC.
The response from the scientific press was swift and pointed.
— Stat headline, May 19, 2020Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine.
The same day, a Los Angeles Times column by Michael Hiltzik put the charge more sharply: "Moderna's vaccine results boosted its share offering – and it's hardly a coincidence." For a company that had spent years being called secretive, the episode sharpened the old criticism. Moderna had disclosed something, but the disclosure was selective, and the selection seemed to serve the share price.
Taken charitably, the logic was a CEO's. A company about to manufacture hundreds of millions of doses of an unapproved product needs capital before the data is complete, and markets do not wait. The uncharitable reading writes itself. Both readings fit the facts, and Bancel's career is full of moments where they coexist.
More friction followed. In July 2020, Reuters reported that Moderna had clashed with government scientists over its reluctance to share clinical trial data. In October, Reuters reported that the trial's contractors had failed to enroll enough people of color, which forced a slowdown in a race where every week counted. In September, in a move one trade publication described as a "bid for transparency," Moderna published the detailed protocol for its Phase III trial. Around the same time, Bancel said that if the trial succeeded, the vaccine might reach the general public by late March or early April 2021.
The pattern that emerges is not a man who keeps secrets so much as a man who treats information the way his molecules do. It is released in deliberate bursts, aimed at a specific receptor, and meant to produce a specific response. Sometimes the receptor was the FDA, sometimes a sovereign buyer, sometimes Wall Street. The risk of this approach is the one he identified in the injected RNA itself: release a signal in the wrong form and the system mistakes it for an infection.
Eleven and one hundred eighty-five
Moderna and NIAID began the Phase III trial in July 2020. The plan was to enroll 30,000 volunteers and split them into two groups. One would receive two 100-microgram doses of mRNA-1273 twenty-nine days apart. The other would receive a placebo of 0.9 percent sodium chloride, saltwater, a cousin of the water injection given to the blue-line animals on Bancel's old slide. Enrollment reached 30,000 in October.
On November 15, 2020, the NIH announced that interim results were positive, and the next day Moderna reported preliminary efficacy of 94.5 percent. On December 18, 2020, the FDA issued an emergency use authorization. It was the first product Moderna had ever had authorized. The company that had raised $2 billion privately and $621 million publicly, signed partnerships with AstraZeneca, Merck, Vertex, and Alexion, and opened a 200,000-square-foot factory reached its first authorization ten years after its founding, during a pandemic.
The final numbers behind that authorization are simple enough to remember. In the vaccine group, 11 of 15,181 people developed COVID-19. In the placebo group, 185 of 15,170 did. There were zero cases of severe disease among the vaccinated and eleven among those who got saltwater. The efficacy was calculated at 94.1 percent and described by outside commentators as "astonishing" and "borderline historic" for a respiratory virus vaccine. The New England Journal of Medicine published the full Phase III results in February 2021.
The comparison everyone made was with the Pfizer–BioNTech vaccine, which showed similar efficacy and arrived days earlier. The race between the two mRNA shots, and among a wider field of competitors, is told in The First Shots, whose subtitle promises "epic rivalries and heroic science." Both are present in Moderna's version. Moderna's competitive edge was not efficacy but temperature. Its vaccine could be kept at 2 to 8 degrees Celsius, the temperature of an ordinary medical refrigerator, for up to thirty days, or at minus 20 degrees for up to four months. The Pfizer–BioNTech vaccine initially needed ultracold storage between minus 80 and minus 60 degrees. Low-income countries generally had cold-chain capacity for standard refrigeration only. The advantage narrowed in February 2021, when the FDA allowed Pfizer's vials to be stored for two weeks at ordinary freezer temperatures. Nature noted that many experts expected the two vaccines' storage requirements to converge over time.
Moderna's vaccine was soon going into famous arms. In January 2021, Vice President Kamala Harris received her second dose of Moderna's vaccine on camera. In the European Union and European Economic Area alone, about 155 million doses had been administered by June 26, 2022, including about 3.1 million to people under 18. The World Health Organization granted emergency use listing on April 30, 2021. Through Takeda, the vaccine reached Japan under the ponderous name "COVID-19 Vaccine Moderna Intramuscular Injection." Its international nonproprietary name was elasomeran, and its brand name became Spikevax. The FDA granted full approval for adults in January 2022.
A body that has received the vaccine does what Bancel had described years earlier to an audience that had never heard of the company. The injected message reaches the cell, the ribosome reads it and makes the protein, the immune system learns to recognize the protein, and the message degrades. Chien's thirty-year wait had been about an instruction that leaves without staying. In the vaccine, the instruction leaves and the immune memory stays.
What a dose is worth
The economics of a pandemic vaccine depend on who is buying and how frightened they are. In June 2020, Singapore signed a pre-purchase agreement, reportedly paying a premium to get early supply, and declined to disclose the price, citing confidentiality clauses. In July, the Financial Times reported that Moderna planned to charge $50 to $60 per course. In August, the U.S. government agreed to buy 100 million doses. In November, Moderna told the German weekly Welt am Sonntag that it would charge governments $25 to $37 per dose, depending on volume, while the European Union pushed for less than $25 on its order of 160 million doses. Canada signed for up to 56 million.
Then, in December 2020, a Belgian budget official posted on Twitter a list of what the EU was paying for each vaccine, a list the officials were not supposed to make public. Moderna's line read $18 per dose. The New York Times reported that the United States was paying $15. A company known for controlling information had its prices exposed by a single tweet.
The money that followed was unprecedented in the company's history and nearly so in the industry's. Moderna's COVID-19 vaccine brought in $200 million in 2020 and $17.7 billion in 2021. Total revenue in 2021 reached $18.47 billion, against $60 million two years earlier, and net income was $12.2 billion. In 2022 revenue rose slightly to $19.26 billion, with net income of $8.36 billion. In April 2021 Moderna announced plans to spend billions to increase production, saying it would make no fewer than 800 million doses that year and could roughly triple output in 2022. An expanded deal with Catalent would let the Indiana plant fill up to 400 vials a minute. In April 2022 Moderna announced a $180 million factory near Montreal under a ten-year partnership with the government of Canada, the province of Quebec, and McGill University, designed to produce 100 million doses a year.
The vaccine had costs that no revenue figure captures. In June 2021, the CDC confirmed that myocarditis or pericarditis occurred in about 13 of every million young people, mostly males over 16, who received either mRNA vaccine. Most recovered quickly. In October and November 2021, Finland, Sweden, Germany, and France recommended against Moderna's vaccine for people under 30. France, Bancel's home country, was among them. There was also "Moderna arm," a delayed skin reaction around the injection site, harmless and widely remarked on.
The intellectual property fights were just as consequential. The lipid nanoparticle delivery system, the fatty envelope that carries the fragile messenger RNA into the cell, drew Moderna into a long patent dispute with Arbutus Biopharma, from which it had previously licensed lipid technology. On September 4, 2020, Nature Biotechnology reported that Moderna had lost a key challenge. In April 2023 a court upheld a decision cancelling one Arbutus patent. In April 2024 another court interpreted the patents at issue the way Arbutus wanted. In August 2022, Moderna sued Pfizer and BioNTech, alleging that their vaccine infringed its mRNA patents. In 2024 GSK sued Moderna in Delaware over the lipid delivery system in both the COVID and RSV vaccines.
In February 2023 Moderna agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research to settle a dispute over a chemical technique used in the vaccine. The Times headline described the payment as coming "after long delay." The government had funded the trials, paid for the doses, and co-developed the vaccine with NIAID, and it had also been owed money for a technique of its own.
The long fall from eighteen billion
Pandemic demand fades as the pandemic does, and Moderna's revenue fell quickly. Revenue was $6.85 billion in 2023, with a net loss of $4.71 billion. In 2024 it was $3.2 billion against a $3.6 billion loss, and in 2025 it was $1.94 billion, with an operating loss of $3.1 billion and a net loss of $2.8 billion. The company ended 2025 with 4,800 employees and $12.3 billion in total assets. The windfall had arrived in a single year and taken three years to drain away.
Bancel's response to the decline was mostly not to retrench. In January 2023 Moderna made its first acquisition in thirteen years, buying OriCiro Genomics, a Japanese maker of genetic engineering tools. That July it agreed with the Chinese government to develop mRNA medicines for exclusive use in China. On May 31, 2024, the FDA approved mResvia, an mRNA vaccine against respiratory syncytial virus for adults 60 and older. It was the third RSV vaccine approved in the United States, which made it a latecomer in a market others had opened. In May 2025 came Mnexspike, a next-generation COVID vaccine. In July 2025 Spikevax won full U.S. approval for high-risk children from six months to eleven years. The pipeline grew to 44 candidates, 37 of them in clinical trials, aimed at HIV, Epstein-Barr virus, Nipah, chikungunya, cytomegalovirus, Zika, and cancer.
One date in that period shows the double life Bancel leads. On November 5, 2024, Bloomberg reported that he was giving up the role of the company's chief sales officer, which he had held on top of being chief executive, while remaining CEO. The founder-era executive who had once run sales in Belgium had been personally overseeing commercial operations at a public company whose sales were collapsing. The same day, the Harvard Street Neighborhood Health Center announced that Brenda and Stéphane Bancel had donated $1.5 million toward a new facility to meet what it called soaring needs. One announcement concerned a fortune under pressure and the other a fortune being given away, and they were dated identically.
The ownership table from these years tells a story of its own. Bancel holds 7.3 percent of the company, more than any other individual. Afeyan, the chairman, holds 5.0 percent. Robert Langer, the academic co-founder, holds 4.0 percent. Stephen Hoge, the president, holds 1.3 percent. The man who joined a year after the founding and was not counted among the founders owns more of it than any of them.
The return of the red line
The cancer program had been there from the start: AstraZeneca in 2013, Onkaido in 2014, Merck in 2015. In early 2023, Moderna and Merck won breakthrough therapy designation from the FDA for mRNA-4157/V940, a personalized cancer vaccine later named intismeran autogene, to be given alongside Merck's immunotherapy pembrolizumab, sold as Keytruda.
On August 6, 2026, the FDA approved Mflusiva, an mRNA influenza vaccine for people 50 and older. Influenza was the first disease Moderna had made an mRNA vaccine against, back in 2015, eleven years before it had an approved flu product. Thirteen days later, on August 19, 2026, the company announced that the combination of its cancer vaccine and Keytruda had reduced the risk of melanoma recurrence and spread in a late-stage Phase III trial. Scientific American called the trial "landmark." The Financial Times reported that Moderna's shares had nearly tripled. The one-day gain was 177 percent. That year Time ranked Moderna first on its list of the World's Most Impactful Companies.
At this point the story returns to Beacon Street, where Bancel stood before the company had a single patient and described what he believed messenger RNA could do. He spoke of a disease of the genome ("by the way, cancer is also a disease of the genome") and of 6,000 rare diseases with no treatments. He spoke of a cardiologist who had waited thirty years for a vehicle and of a team that went "straight into monkeys" because mice lie, and of a company founded on what the founders called a "crazy idea" that its CEO kept describing as obvious.
The last image he showed that day was not a chart. It was a photograph of two cross-sections of a heart, each taken one year after a heart attack. In the top one, from an animal that got water, a broad pale scar ran through the muscle wall. In the bottom one, from an animal that got a single injection of a message that had disappeared from its body 363 days before the photograph was taken, the muscle had grown back.
Part IIThe Playbook
The principles below are drawn from what Bancel did, not what he says he did, though in his case the two diverge less than usual. Many of them were stated plainly on a TEDx stage years before they were tested. Others show up only in the sequence of deals, raises, and disputes recorded above. Several are uncomfortable. A playbook taken from a career this full of tension should show the costs alongside the wins.
The principles
- 1.Build around the obvious question nobody has industrialized.
- 2.Concentrate the cap table to concentrate attention.
- 3.Pay for the expensive proof first.
- 4.Go dark to go deep, then choose when to turn on the lights.
- 5.Sell options on the platform, not the platform.
- 6.Let other people's urgency fund your optionality.
- 7.Build the factory before the product.
- 8.Treat logistics as a feature.
- 9.Raise when the window opens, and know what the window costs.
- 10.Assume the windfall is a 48-hour message.
- 11.Fight for the infrastructure IP, and pay your debts before they compound.
- 12.Keep the founding thesis alive through the detour.
Principle 1
Build around the obvious question nobody has industrialized
Bancel's founding pitch was striking for how little it claimed. He did not say Moderna had discovered a new biology. He said the body already makes proteins from messenger RNA trillions of times a day, so "from what I've explained to you is pretty obvious, mRNA are drugs, why not?" The opportunity was in the gap between something scientifically obvious and something commercially impossible. The idea was simple, and the barriers (immunogenicity and instability) were hard enough that no one had built a company to get past them.
Questions like that are unusually valuable because they are easy to explain to investors, partners, and regulators while the execution remains hard to copy. A complex idea needs a defense. An obvious idea with known barriers needs only a solution to those barriers. Bancel's two-barrier framing ("these two things") converted a vague ambition into an engineering specification that could be checked off.
Tactic: List the ideas in your field that every expert agrees would work "if only" two specific obstacles were solved, and build a company around solving exactly those two.
Principle 2
Concentrate the cap table to concentrate attention
"We first chose to have only one investor," Bancel said. Conventional wisdom spreads early risk across many funds. Bancel accepted more financial risk to remove a different danger: a boardroom of investors "fighting for how much money they were going to make." On his reasoning, a fragmented cap table is a fragmented agenda, and a platform that takes years to validate cannot survive constant negotiation over priorities.
The decision also made the 2011–2017 fundraising unusual. Moderna raised roughly $2 billion privately, much of it before it had published meaningfully, in part because the early structure let it raise on conviction instead of syndicated consensus. The cost was dependence. When the patron's view and the market's view diverge, a concentrated cap table has nowhere to turn.
Tactic: In the first phase of a long-horizon company, optimize for investor alignment over investor count, and write down in advance which decisions you are protecting from committee.
Principle 3
Pay for the expensive proof first
"Mice and rats, if it worked, it will be known," Bancel said, and went "straight into monkeys. Very atypical. Cost a bloody fortune." Most startups run the cheapest experiment that could produce an encouraging result. Bancel ran the experiment most likely to predict whether the product would work in people, even though it cost far more.
The logic is about avoiding false positives. A cheap experiment that succeeds tells you little and encourages you to keep going. An expensive experiment that fails saves you from a decade of false hope, and one that succeeds is believed. The same instinct showed up in the cardiac data Bancel chose to present. He did not show an acute biomarker. He showed one-year survival and a one-year cross-section of the heart.
Tactic: Identify the experiment that would most convince a skeptical expert, price it, and run it before the cheaper experiments that would only convince you.
Principle 4
Go dark to go deep, then choose when to turn on the lights
"For 18 months, no website. No press release, no nothing." Bancel's secrecy protected focus, and it protected a lead in a field where the core insight, once published, could be copied by better-funded incumbents. It also earned Moderna years of skeptical coverage, from Stat's "most secretive startups" in 2016 to the July 2020 dispute with government scientists over trial data.
The useful lesson is not secrecy itself. It is deliberate disclosure. Moderna opened up when it needed to: in 2017, when Science reported the company "revealing the secrets"; in September 2020, when it published its Phase III protocol as a "bid for transparency." The trouble came when the timing of a disclosure seemed to serve the share price instead of the science, as in May 2020.
◐
Silence and Disclosure
Moderna's information strategy alternated between opacity and selective openness.
| Moment | Posture | Result |
|---|---|---|
| Founding stealth period | Dark | "18 months, no website"; focus on the science |
| 2016 Stat investigation | Exposed | Reported culture of secrecy, little outside review |
| February 2017 Science | Opening | "Revealing the secrets behind its new drugs and vaccines" |
| May 2020 interim data | Selective | Eight participants' data paired with $1.25B raise; expert criticism |
| September 2020 trial protocol | Transparent | Detailed Phase III plan published |
Tactic: Decide in advance what you will disclose and when, and never let a disclosure and a financing share the same day unless you are prepared to defend the coincidence.
Principle 5
Sell options on the platform, not the platform
Between 2013 and 2016 Moderna signed AstraZeneca, Alexion, Merck, and Vertex, and spun out Onkaido, Valera, and Elpidera. Each deal sold access to one application of a technology whose real value was that it applied everywhere. Partners paid for a seat in a specific therapeutic area. Moderna kept the format.
The structure turned partners' budgets into Moderna's research funding while preserving the company's ability to capture the platform's full value later. It also spread the validation risk: if a single application worked, it lent credibility to all of them. The Alexion termination in 2017 showed the downside. An option can expire very publicly, and a platform company's setbacks are read as verdicts on the whole platform.
Tactic: If your core asset is a capability rather than a product, license narrow, field-specific rights to large partners and keep the cross-field rights.
Principle 6
Let other people's urgency fund your optionality
DARPA's $25 million in 2013 funded a goal—suppressing a pandemic within sixty days—that seemed theoretical at the time. The Gates Foundation's $20 million in 2016 funded global health work. In 2020, BARDA, by one accounting, funded 100 percent of the cost of bringing the COVID vaccine to licensure. In each case the funder's urgency was not Moderna's commercial priority, and in each case the money paid for capabilities Moderna would keep.
The pattern says something about where non-dilutive money comes from. Governments and foundations fund preparedness, and preparedness is optionality by definition. A platform that can respond to many threats is worth more to a defense agency than a single product, and the agency's money builds the platform.
Tactic: Map the threats that governments and foundations are paid to worry about, and position one application of your core technology as the answer to each.
Principle 7
Build the factory before the product
Moderna opened its 200,000-square-foot Norwood facility in July 2018, more than two years before it had an authorized product. When the pandemic came, Norwood joined Lonza, Catalent, Rovi, and Aldevron in a network that would aim to produce at least 800 million doses in 2021. Manufacturing capacity that looked like premature spending in 2018 became, in 2020, the bottleneck that separated the vaccine makers that could deliver from those that could not.
The principle works because in biologics the process is part of the product. A company that owns its manufacturing learns things about its molecule that a company outsourcing everything never will, and it can scale faster when demand arrives.
Tactic: If manufacturing knowledge will be a constraint once you succeed, start building it before you need it, while the cost of learning is still low.
Principle 8
Treat logistics as a feature
Moderna's vaccine matched its main rival's efficacy, but it could sit in a standard medical refrigerator for thirty days while the rival initially required ultracold freezers. In a world where low-income countries generally had only standard cold chains, temperature was part of the product's value. The advantage narrowed within months as Pfizer's storage rules relaxed, but it mattered during the period of greatest scarcity.
Operators tend to treat distribution as a cost center that comes after the product is finished. For anything that has to move through physical systems—hospitals, pharmacies, warehouses—the receiving end's constraints are part of the product specification.
Tactic: Write down the worst-equipped location that must be able to use your product, and design to its constraints before you design to your ideal customer's.
Principle 9
Raise when the window opens, and know what the window costs
In May 2020, Moderna released interim antibody data on eight participants and announced a $1.25 billion share sale at a $30 billion valuation. The company had a manufacturing scale-up to fund and a market eager to buy. It also drew Stat's "didn't produce data critical to assessing" headline and the Los Angeles Times charge that the timing was "hardly a coincidence."
Both things were true, and that is the lesson. Capital windows are real and they close. A CEO who waits for perfect data may be unable to fund the factory that the data justifies. A CEO who raises on imperfect data borrows against his credibility, and that debt comes due with regulators, scientists, and the public at the worst possible moment.
Tactic: When you raise into a window, publish the limits of your data in the same breath as the data itself, so that skeptics hear the caveats from you first.
Principle 10
Assume the windfall is a 48-hour message
Moderna's revenue went from $60 million in 2019 to $18.47 billion in 2021 to $1.94 billion in 2025. The windfall behaved exactly like the molecule that produced it: a short, intense burst of signal followed by rapid decay. What remained was the capability built with the money—the manufacturing network, the pipeline of 44 candidates, the cancer program—not the revenue run rate.
$
Revenue Phases
Moderna's financials, in millions of U.S. dollars, sorted by phase.
| Year | Revenue | Net income (loss) | Phase |
|---|---|---|---|
| 2019 | 60 | (514) | Build |
| 2020 | 803 | (747) | Build |
| 2021 | 18,471 | 12,202 | Windfall |
| 2022 | 19,263 | 8,362 | Windfall |
| 2023 | 6,848 | (4,710) | Contraction |
| 2024 | 3,200 | (3,600) | Contraction |
| 2025 | 1,900 | (2,800) | Second act |
The question for any company that has one extraordinary year is what that year leaves behind. Moderna's answer was products that would arrive years later: mResvia in 2024, Mnexspike in 2025, Mflusiva and the melanoma data in 2026. That was too late to cushion the decline, but early enough to change the company's story.
Tactic: In a windfall year, budget the windfall as one-time capital and commit it to assets that will still produce value when the revenue is gone.
Principle 11
Fight for the infrastructure IP, and pay your debts before they compound
The fights that defined Moderna's post-pandemic years were not about the messenger RNA sequence. They were about the delivery system, the lipid nanoparticle, and about chemical techniques that belonged partly to others. Arbutus, GSK, and Pfizer–BioNTech all fought over the infrastructure, not the payload. The $400 million settlement with the NIH, Dartmouth, and Scripps in February 2023 came "after long delay," as the Times put it, and the delay cost Moderna goodwill with the agency that had co-developed its only product.
Platform companies are especially exposed here, because the platform is the infrastructure. Every product inherits the platform's legal liabilities.
Tactic: Audit the licenses and third-party techniques underneath your core platform now, and settle the ones you will eventually owe before your success makes them more expensive and more public.
Principle 12
Keep the founding thesis alive through the detour
On Beacon Street, Bancel's case for messenger RNA was rare disease, cardiac repair, and cancer, "also a disease of the genome." He did not lead with vaccines. The pandemic made Moderna a vaccine company, and for three years the market valued it as one. Through those years the company kept the Merck cancer partnership it had signed in 2015, and in August 2026 that program produced Phase III melanoma results that sent the stock up 177 percent in a day.
▲
The Long Arc
From founding thesis to second act.
2010
Moderna founded in September by Rossi, Springer, Chien, Langer, and Afeyan.
2011
Bancel arrives as CEO from bioMérieux.
2013
AstraZeneca deal; DARPA grant to target pandemic response within 60 days.
2015
First mRNA vaccine (influenza); Merck cancer partnership.
2018
Norwood facility opens; record $621 million IPO.
2020
mRNA-1273 authorized December 18, Moderna's first product.
2021
Revenue reaches $18.47 billion.
2023
Breakthrough designation for cancer vaccine; revenue falls to $6.85 billion.
2024
mResvia approved; Bancel steps down as sales chief.
2026
Mflusiva approved; Phase III melanoma success; shares up 177% in one day.
The lesson is not that the detour was a mistake. It funded the second act. The lesson is that a company that forgets why it was founded during its most profitable period may find, when that period ends, that it has nothing left to return to.
Tactic: During any period when circumstance redefines your company, protect a fixed share of resources for the original thesis, and review it as if the circumstance were about to end.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
— Stéphane Bancel, TEDxBeaconStreetSo few of us, couple years ago, sitting in Cambridge, Massachusetts, thought about the following crazy idea: "What if mRNA could be a drug?"
— Stéphane Bancel, TEDxBeaconStreetWhen you understand you have a technology that can change the society and impact so many millions of lives, how do you build that company?
— Stéphane Bancel, TEDxBeaconStreetSo we went straight into monkeys. Why? Because monkeys are the closest animals to humans. We went straight into monkeys. Very atypical. Cost a bloody fortune.
— Stéphane Bancel, TEDxBeaconStreetThe mRNA gets degraded, after 48 hours it's gone, but the VEGF is here and it has instructed the stem cell to regrow your heart.
— Stéphane Bancel, TEDxBeaconStreetWe feel this is, most probably, the only time in our lives that we have the chance to really change the world.
Maxims
- Industrialize the obvious. The best foundational bets are ideas experts already accept but no one has engineered past two specific barriers.
- One investor, one agenda. A concentrated cap table buys the patience a long platform needs, at the price of dependence.
- Buy the expensive truth early. Run the experiment a skeptic would trust, not the one that flatters you.
- Secrecy is a timetable, not a personality. Go dark to protect the work, and decide in advance when the lights come on.
- Sell the fields, keep the format. License narrow applications and retain the platform that spans them.
- Preparedness money builds platforms. Governments and foundations fund optionality; position your capability as their answer.
- The factory comes first. In biology, the process is part of the product, and capacity built early becomes the bottleneck everyone else lacks.
- Design for the worst-equipped user. A refrigerator can matter as much as an efficacy percentage.
- A windfall is a message, not a revenue line. It fades quickly; measure it by what it leaves behind.
- Return to the first question. The thesis that founded the company is usually the one that saves it after the detour.
